Table 4.
Comparison of changes in the clinical and biochemical parameters during the study period between the intervention and control groups across glibenclamide, metformin, and metformin + glibenclamide treatment subgroups.
| Glibenclamide | Metformin | Glibenclamide + metformin | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control group | Intervention group | P value | Control group | Intervention group | P value | Control group | Intervention group | P value | |
| Systolic blood pressure | 0.01 (−5.00, 1.25) |
−10.00 (−16.25, −3.75) |
0.016* | 0.01 (−1.25, 10.00) |
−10.00 (−10.00, 0.01) |
0.043* | 0.01 (0.01, 5.00) |
−10.00 (−12.50, −2.50) |
0.003* |
| Fasting glucose | 13.0 (4.50, 31.50) |
−25.00 (−84.50, −5.75) |
<0.0001* | 2.00 (−3.50, 12.00) |
−25.00 (−32.00, −10.00) |
0.005* | 7.00 (1.00, 22.00) |
−32.00 (−47.50, −22.50) |
<0.0001* |
| Insulin | 0.06 (−3.85, 5.39) |
−4.42 (−7.85, −2.31) |
0.042* | 0.73 (0.06, 1.05) |
−1.32 (−3.39, −0.04) |
0.088 | 0.37 (0.32, 0.95) |
−7.71 (−9.31, −1.96) |
0.002* |
| HbA1c | −0.15 (−1.04, 0.200) |
−1.55 (−2.22, −0.97) |
0.031* | −0.15 (−0.70, 0.22) |
−0.60 (−2.00, −0.02) |
0.133 | 0.05 (−0.10, 0.50) |
−1.10 (−2.05, −0.90) |
<0.0001* |
| HOMA-IR | 0.17 (−1.53, 3.69) |
−2.12 (−5.07, −1.16) |
0.022* | 0.27 (0.15, 0.65) |
−0.86 (−1.25, −0.31) |
0.043* | 0.24 (−0.26, 0.56) |
−2.86 (−5.22, −1.12) |
<0.0001* |
| HDL-cholesterol | −1.65 (−5.77, 1.40) |
6.25 (2.82, 11.26) |
0.003* | 0.10 (−4.07, 2.95) |
4.60 (1.40, 12.05) |
0.043* | −2.80 (−4.70, 0.60) |
6.10 (0.35, 11.20) |
<0.0001* |
| LDL-cholesterol | 8.0 (5.50, 18.0) |
−17.50 (−35.75, −10.50) |
0.005* | 4.50 (−1.25, 20.75) |
−7.0 (−70.00, 2.00) |
0.007* | 1.00 (−2.00, 4.00) |
−9.00 (−32.00, 1.50) |
0.030* |
Data is presented as medians (Interquartile ranges). *P < 0.05 versus control group. HOMA-IR: homeostasis model of assessment for insulin resistance; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein.